Will you lose access to your compounded GLP-1
For research peptides such as AOD-9604, CJC-1295, Ipamorelin, and similar compounds, the answer is: there is not enough evidence to make a confident clinical claim
Conducted between June 2011 and March 2013 at 191 sites in 27 countries in Europe, North America, South America, Asia, and Australia this was a randomised, placebo-controlled trial designed to evaluate the efficacy and safety of 3mg liraglutide 'injected subcutaneously once daily, as an adjunct to a reduced-calorie diet and increased physical activity, for weight management in overweight or obese adults who did not have diabetes at baseline.' A total of 3,731 individuals participated in the trial, of whom 2,487 were assigned to lifestyle intervention plus liraglutide and 1,244 to lifestyle intervention with a placebo
Were always available to discuss what approach might work best for your situation
This section explores its impact on cardiovascular health and neurological disorders